Predict your next investment

Corporation
ipcalabs.com

See what CB Insights has to offer

Investments

1

Partners & Customers

3

About Ipca Laboratories

Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. The company manufactures formulations, APIs, and drug intermediates with a portfolio consisting of anti-malarial, pain management, anti-emetics, antibiotics, analgesics, anti-diabetics, and cardiovascular products, and products for cough and cold therapy, skin problems, and problems with the central nervous system.

Ipca Laboratories Headquarter Location

142 AB, Kandivli Industrial Estate, Kandivli

Mumbai, 400 067,

India

+91 (22) 6647 4747

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Ipca Laboratories News

Ipca Labs To Granules India: Bulk Drug Makers' Q3 Margin Under Pressure

Jan 20, 2022

8:24 AM IST, 20 Jan 2022 8:24 AM IST, 20 Jan 2022 8:24 AM IST, 20 Jan 2022 Save Some of Indian drugmakers’ best-performing business after the Covid-19 pandemic struck in 2020 is likely to be a drag in the third quarter.Analysts and makers of active pharmaceutical ingredients—raw materials that go into medicines—indicated that their margin may contract in the three months through December as input costs continue to surge.The bulk drug makers saw a 40-50% inflation impact in the second quarter, Abdulkader Puranwal... Some of Indian drugmakers’ best-performing business after the Covid-19 pandemic struck in 2020 is likely to be a drag in the third quarter. Analysts and makers of active pharmaceutical ingredients—raw materials that go into medicines—indicated that their margin may contract in the three months through December as input costs continue to surge. The bulk drug makers saw a 40-50% inflation impact in the second quarter, Abdulkader Puranwala, pharma analyst with Elara Capital, told BloombergQuint. “For Q3, inflation impacted the gross margins through all the three months.” That will impact earnings for the quarter ended December for companies that initially benefited from higher demand for domestic bulk drugs as India imposed curbs after a border standoff with China. While the nation has offered incentives do drive local production, China is still the biggest supplier and its latest pollution curbs has driven prices higher. According to Nirmal Bang’s pharma analyst Vishal Manchanda, prices of basic raw materials to all API companies such as acetic acid and methanol have almost doubled in a year. Ajit Kumar Jain, joint managing director at Ipca Laboratories Ltd., said during a second-quarter earnings call that raw material prices have moved up two to threefold in some cases due to shortages arising from China’s so-called dual-control policy, setting targets for provinces to cap energy consumption and increase efficiency. That means key provinces where suppliers of chemicals and intermediates are located were operational only for few days a week. According to Manchanda: Price of para amino phenol, the key raw material for paracetamol, has almost doubled, impacting Granules India Ltd. and GlaxoSmithKline Pharmaceuticals Ltd. The raw material, dicyandiamide, to Metformin—an oral diabetes treatment drug—has witnessed over a 50% year-on-year increase in price. This could possibly impact Granules India, Aarti Drugs Ltd., IOL Chemicals & Pharmaceuticals Ltd. and Ipca Labs. Artemisinin, an antimalarial ingredient, has also seen a price rise of 50%. It can impact drugmakers such as Ipca Labs. Prices of 6-APA and penicillin potassium, key ingredients in antibiotic manufacturing, have gone up 30–40%. This may weigh on Lupin Ltd. and Aurobindo Pharma Ltd. BloombergQuint awaits responses to queries emailed to Ipca Labs, Granules India, Aarti Drugs, IOL Chemicals, GSK, Lupin and Aurobindo Pharma. Investors have possibly gauged the impact on margin. Some stocks, Puranwala said, are witnessing “pre-result corrections”. Granules India, among others, had seen price inflation narrow its gross margin to 50.9% in the second quarter from 57.9% a year earlier. Margin on paracetamol was the most impacted. Higher freight costs and short-term inability to pass on the input price hikes to customers added to its woes. The company said in the Q2 earnings call it would be able to pass on substantial portion of these price hikes to customers but didn’t give a timeline. According to Ipca Labs, there will be a time lag of around four to five months before the whole industry can pass on these price increases. “We have almost around three to four months order in pipeline always. So on those orders, prices cannot be revised,” Jain said. Hence, “the hiked raw material and energy prices cannot be passed on to the customers immediately”. Earlier in January 2022, analysts had said multiple headwinds such as rising cost of raw inputs and demand volatility facing the bulk drug makers are likely to normalize in the new year, potentially boosting profitability. Stay Updated With Business News On BloombergQuint Get Regular Updates

Ipca Laboratories Investments

1 Investments

Ipca Laboratories has made 1 investments. Their latest investment was in Lyka Labs as part of their Corporate Minority on November 11, 2021.

CBI Logo

Ipca Laboratories Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/24/2021

Corporate Minority

Lyka Labs

Yes

1

Date

11/24/2021

Round

Corporate Minority

Company

Lyka Labs

Amount

New?

Yes

Co-Investors

Sources

1

Ipca Laboratories Acquisitions

2 Acquisitions

Ipca Laboratories acquired 2 companies. Their latest acquisition was Ramdev Chemical on April 24, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/24/2019

$99M

Acquired

1

1/17/2018

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

4/24/2019

1/17/2018

Investment Stage

Debt

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$99M

Note

Acquired

Subscribe to see more

Sources

1

10

Ipca Laboratories Partners & Customers

3 Partners and customers

Ipca Laboratories has 3 strategic partners and customers. Ipca Laboratories recently partnered with NetApp on September 9, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

9/28/2015

Vendor

NetApp

United States

Ipca chooses NetApp to help efficiently store and easily access critical medical data from 14 locations

Ipca chooses NetApp to help efficiently store and easily access critical medical data from 14 locations .

1

6/9/2015

Partner

Amyris

United States

Subscribe to see more

Subscribe to see more

10

6/2/2014

Partner

Outlook Therapeutics

United States

Subscribe to see more

Subscribe to see more

10

Date

9/28/2015

6/9/2015

6/2/2014

Type

Vendor

Partner

Partner

Business Partner

NetApp

Amyris

Outlook Therapeutics

Country

United States

United States

United States

News Snippet

Ipca chooses NetApp to help efficiently store and easily access critical medical data from 14 locations

Ipca chooses NetApp to help efficiently store and easily access critical medical data from 14 locations .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Ipca Laboratories Team

1 Team Member

Ipca Laboratories has 1 team member, including former Executive Vice President, Buchi Reddy Reguri.

Name

Work History

Title

Status

Buchi Reddy Reguri

Executive Vice President

Former

Name

Buchi Reddy Reguri

Work History

Title

Executive Vice President

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.